Recent success of antibodies targeting inhibitory immune checkpoints such as CTLA-4 and PD-1 has again shifted the focus on inhibitory molecules in immune cell signalling for a beneficial anti-tumor response [82]. This evidence concerns the gene CTLA4 and neoplasm.